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Abstract 
Background: There is debate about the psychometric characteristics of the EQ-5D-3L for use in  
epilepsy.  In response to these concerns, an epilepsy-specific preference-based measure (NEWQOL-
6D) was developed. However the psychometric characteristics of NEWQOL-6D have not been 
assessed.  The aim of this study was to investigate the validity and responsiveness of EQ-5D-3L and 
NEWQOL-6D for use in the assessment of treatments for newly diagnosed focal epilepsy.  
 
Methods: The analysis used data from the Standard And New Antiepileptic Drugs (SANAD) trial 
including patients with focal epilepsy.  We assessed convergent validity using correlations, and known 
group validity across different epilepsy and general health severity indicators using ANOVA and effect 
sizes. The responsiveness of the measures to change over time was assessed using standard 
response means (SRM). We also assessed agreement between the measures. 
 
Results: There was some level of convergence and agreement between the measures in terms of 
utility score, but divergence in the concepts measured by the descriptive systems. Both instruments 
displayed known group validity, with significant differences between severity groups, and generally 
slightly larger effect sizes for NEWQOL-6D across the epilepsy specific indicators.    Evidence for 
responsiveness was less clear, with small to moderate SRMs demonstrating different levels of change 
across different indicators. 
 
Discussion: There was an overall tendency for the NEWQOL-6D to better reflect differences across 
groups, but this does not translate into large absolute utility differences. Both the EQ-5D-3L and 
NEWQOL-6D show some evidence of validity for providing utility values for economic evaluations in 
newly diagnosed focal epilepsy.  
 3 
 
Introduction 
In the economic evaluation of health technologies, the Quality-Adjusted Life-Year (QALY) is often the 
preferred measure of health outcome.  The QALY combines a period of time spent in a health state 
and the associated quality of life into a single figure to assess the overall effectiveness of treatments.  
The quality aspect of the QALY is known as health utility, and can be derived from preference-based 
measures of health such as the EQ-5D-3L, which has a utility value set based on the preferences of 
the general population, and is anchored at 1 (equivalent to full health) and 0 (equivalent to dead).  
 
Epilepsy is a neurological disorder characterised by unprovoked, recurring seizures. There are 
different types of seizures, with focal (partial onset) seizures originating within specific areas on the 
brain [1].  It is a prevalent condition, and is present in around 1% of the ZRUOG¶Vpopulation [2].  
Patients newly diagnosed with epilepsy are usually initiated on antiepileptic drug treatment, with dose 
and subsequent regimens adapted according to treatment response and tolerability. For those whose 
seizures are difficult to control, multiple concurrent therapies can be used to maximise seizure control 
[3,4].  Given the nature of the condition, epilepsy and antiepileptic drug treatment both have a range 
of impacts on Health Related Quality of Life (HRQL) including on mental health (for example anxiety 
about the onset of seizures), and cognitive and social functioning.   
 
For the economic evaluation of treatments for epilepsy, it is important to measure the HRQL (and 
utilities) of the patient groups receiving treatment, and the EQ-5D-3L is often used for this purpose.  
However, although EQ-5D-3L is a generic measure, and is used to compare health status across 
conditions, there is evidence suggesting that it may lack some level of validity for use in epilepsy.  
Stavem and colleagues [5] found that a number of the EQ-5D-3L dimensions did not discriminate well 
between patients using antiepileptic drugs and patients with neurologic comorbidities. Furthermore, 
the EQ-5D-3L may not capture all of the HRQL dimensions relevant to epilepsy patients [6], and may 
not be sensitive to seizure control [7].  In terms of responsiveness, EQ-5D-3L may be insensitive to 
health status at the upper end GXHWRDFHLOLQJHIIHFWZLWKPDQ\SDWLHQWVUHSRUWLQJWKHµEHVW¶KHDOWK
state, with no problems, on the measure). Furthermore, the recall period of one day may impact the 
sensitivity of the instrument when used for episodic conditions such as epilepsy [8].  
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In response to these findings, an epilepsy-specific preference based measure was developed for use 
in the assessment of HRQL (NEWQOL-6D) [9].  NEWQOL-6D was developed using baseline data 
from the Standard and New Anti-Epileptic Drugs (SANAD) study [10]. SANAD included patients with 
predominantly newly developed focal epilepsy for whom one treatment (carbamazepine) was 
considered the standard treatment, and who were randomly assigned to receive treatment as usual or 
one of four other treatments (gabapentin, lamotrigine, oxcarbazepine, or topiramate).  Condition 
specific preference based measures may improve health care decision making in areas where the 
psychometric validity of generic measures is lacking by providing more precise utility values that are 
based on the dimensions of HRQL impacted by the condition.  However it is currently unclear whether 
NEWQOL-6D provides an improvement in the validity of utility values generated for the calculation of 
QALYs, and therefore psychometric evidence comparing generic and condition specific measures is 
required. 
 
The aim of this study was to investigate the psychometric performance of the EQ-5D-3L and 
NEWQOL-6D to provide evidence for the use of the utility values generated in the assessment of 
epilepsy treatments in newly diagnosed focal epilepsy patients using an existing dataset. This 
includes the following objectives: 
1. To assess the psychometric validity of the EQ-5D-3L and NEWQOL-6D  
2. To assess the responsiveness (i.e. change in utility) of EQ-5D-3L and NEWQOL-6D to 
clinical outcomes in newly diagnosed focal epilepsy. 
 
Methods 
Measures - EQ-5D-3L  
The EQ-5D-3L [11] is the most widely used generic preference based measure internationally. It is 
recommended by the National Institute for Health and Care Excellence (NICE) in the UK for use in the 
economic evaluation of interventions [12], and is accepted by other reimbursement agencies around 
the world [13,14].  EQ-5D-3L measures health across five dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) each with three response levels (none, some and 
extreme/unable), and therefore describes 243 (35) health states.  A selection of health states were 
valued by a representative sample of the UK general population using the Time Trade-off (TTO) 
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preference elicitation technique [15].  This produced a utility scale with a range from 1 for the best 
state, 11111, to -0.594 for the worst state, 33333, where negative values are equivalent to states 
valued as worse than dead [15]. The visual analogue scale (EQ-VAS, which reports health on a 0 
(worst imaginable) to 100 (best imaginable) scale) was also collected and used to provide an 
indication of the overall health of the sample. 
 
Measures - NEWQOL-6D 
The NEWQOL-6D [9] was developed from the NEWQOL instrument [16] using the baseline data from 
a large randomised controlled trial of anti-epileptic drugs, (the SANAD study, see dataset section). 
NEWQOL-6D assesses epilepsy specific HRQL across six dimensions (worry about attacks 
(seizures); depression; memory; concentration; control; stigma) each with four severity response 
levels, therefore describing 4096 (46) possible health states.  To produce the utility scale, 50 health 
states were valued by a representative sample of the UK general population using TTO (to promote 
comparability with the UK EQ-5D-3L tariff [15]).  This produced a value set with a range from 0.954 
(for the best state 111111) to 0.341 for the worst state, 444444,. Further work with the instrument has 
shown that general population and patient valuations of NEWQOL-6D health states have limited 
differences [17].   
 
Dataset 
The SANAD data [10] from three time points (baseline, year 1 and year 2) was used for the analysis,. 
The data for each time point includes the EQ-5D-3L, the NEWQOL battery [16] which allows the 
NEWQOL-6D to be calculated, and a range of clinical and other health indicators, including the 
number of seizures, self-reported health change over the last year, cognitive problems, healthcare 
services received.   The Hospital Anxiety and Depression Scale (HADS) [18], a widely used measure 
of anxiety and depression that provides cut offs for possible and probable caseness, was also used 
as a comparative measure. Patients with complete data for each of the measures across each time 
point were included. 
 
Analysis 
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A range of psychometric analyses were carried out to assess the validity and responsiveness of the 
EQ-5D-3L and NEWQOL-6D. 
 
Descriptive analysis 
The means, standard deviations, medians, ranges and completion rates of the utility scores for each 
of the measures at each time point were assessed.  
 
Validity 
Psychometric analysis of validity assesses the extent to which an instrument measures what it is 
intended to measure (in this case HRQL).  It should be noted that validity of patient-reported outcome 
measures such as EQ-5D-3L and NEWQOL-6D is difficult to prove, as in many health conditions 
tKHUHLVUDUHO\DµJROGVWDQGDUG¶DJDLQVWZKLFKWRFRPSDUH7Kis is the case in epilepsy, where many 
of the measures lack in psychometric evidence, and means that validity is compared across 
measures using various well established tests and guidelines about the magnitude of the relationship.  
 
Concurrent validity 
Concurrent validity assesses the strength of the relationship between measures of the same concept 
using Pearson correlations.  Strong correlations indicate that the preference-based measures are 
assessing related constructs. Correlations are considered weak if scores are <0.3, moderate if scores 
DUHDQGDQGVWURQJLIVFRUHVDUH [19]. Correlations between the EQ-5D-3L and 
NEWQOL-6D utility scores and dimensions at each time point (baseline, year 1, year 2) were 
assessed. 
 
Agreement between the utility values was assessed using Bland Altman plots, which are used to 
visualise the relationship between measures scored on the same scale.  This was done by plotting the 
mean of the EQ-5D-3L and NEWQOL-6D values against the difference (NEWQOL-6D minus EQ-5D-
3L) and assessing the number of plots outside the agreement range (+/- 2 SD from the mean) [20]. 
 
Known group validity 
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Known group validity assesses the extent to which scores on an instrument differ across groups 
where they are expected to differ (for example severity groups).  This was measured using ANOVA 
difference tests, and by calculating effect sizes between the groups, which provide a standard 
indicator of the size of the difference, and are calculated as Score 2 ± Score 1/Standard deviation of 
Score 1.  Effect sizes of less than 0.2 are considered small, 0.5 moderate, and 0.8 large [19].  We 
assessed differences in EQ-5D-3L and NEWQOL-6D utility scores at baseline across a range of 
groups: 
a. Total number of seizures at baseline (defined as four groups: 1-3, 4-5, 6-9 and 10+ total 
lifetime seizures).  
b. Self-reported health status (defined as three groups from a five point Likert scale: very 
good/excellent, good, and fair/poor) 
c. Remission status (two groups: remission and no remission, where remission was defined 
as no attack in the past year).  This was carried out at year 1 and year 2, and can be 
interpreted as known group validity because the utility of those in different frequency 
groups can be assessed at one time point. 
d. HADS anxiety and depression dimension caseness cut offs at baseline (defined as no 
case (a score below 8) and possible case (a score of 8+)).  
 
Responsiveness 
Responsiveness assesses the ability of an instrument to detect changes in HRQL over time.  
However, responsiveness is difficult to prove DVWKHUHLVQRµWUXH¶UHIHUHQFHPHDVXUHRI+54/.  
Therefore clinical variables that are expected to have an effect on HRQL are used to identify groups 
of patients whose HRQL is expected to have changed, and the responsiveness of the utility measures 
is compared across the groups.  We assessed responsiveness for full completers at each time point, 
and compared baseline to year 1, and baseline to year 2, by assessing mean change in utility overall, 
and across identified change groups using the Standardised Response Mean (SRM; (T2 ± T1)/SD of 
change), which is a standard indicator of change across measures and time points.  SRMs of less 
than 0.2 are considered small, 0.5 moderate, and 0.8 large [19]. The following analyses were carried 
out: 
 8 
 
a. Assessment of floor and ceiling effects: If a large proportion are at the floor (lowest 
possible score) or ceiling (highest possible score) then this impairs the ability of the 
measure to pick up decreases or increases in HRQL respectively.  
b. Mean change and SRMs based on self-reported health transition anchor (assessing 
whether health has improved, stayed the same or worsened over the last year). 
c. Mean change and SRMs based on remission, defined as those with no seizures during 
the past year. This was done between Y1 and Y2 as it is difficult to interpret baseline 
frequency in terms of when the attacks occurred outside the SANAD study period. 
although the sample consists of newly diagnosed patients, the exact time of seizure 
occurrence is unclear. 
d. Change in the actual NEWQOL-6D and EQ-5D-3L health states reported over time 
 
Results 
Sample characteristics 
The characteristics of the sample at baseline are reported in Table 1, with the sample size at years 1 
and 2 also indicated. A slight majority of the sample (55%) were male and the mean age was 40.  The 
mean EQ-VAS score was 68, with a wide range of health reported (from 5 to 100). 
 
Descriptive analysis 
The completion rate of EQ-5D-3L was higher than NEWQOL-6D.  Descriptive statistics for EQ-5D-3L 
and NEWQOL-6D are reported in Table 2.  The mean EQ-5D-3L scores are lower than the NEWQOL-
6D across each time point, with a larger standard deviation. The median of the EQ-5D-3L is higher in 
each case, reflecting the skewed nature of the data. The EQ-5D-3L data is bimodal, with a large 
number of responses at 1, whereas NEWQOL-6D is unimodal. Bimodal EQ-5D-3L data is common 
due to the difference in utility values between the best state (11111 with a utility of 1), and the next 
best state (11211 with a utility of 0.883).   
 
Concurrent validity 
Correlations indicate moderate convergence between the EQ-5D-3L and NEWQOL-6D utility scores 
at baseline (0.617), year one (0.651) and year two (0.647).  However, the correlations between the 
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NEWQOL-6D and EQ-5D-3L dimensions at baseline reported in Table 3 indicate a low level of 
overlap except for the depression dimension. only baseline correlations are reported as the 
correlation pattern is similar at both follow up time points.  Figure 1 displays the Bland Altman plot at 
baseline, with the central line indicating the mean, and the lines either side indicating 2 x SD away 
from the mean, and shows that disagreement between the measures is larger at the more severe end 
of the scale, where the mean of the measures is low, and many data points are outside the limits of 
agreement. The relationship is similar at both follow up time points. 
 
Known group validity 
Table 4 demonstrates that both EQ-5D-3L and NEWQOL-6D significantly discriminate between 
groups defined by number of seizures (EQ-5D-3L: (F(2,1543) = 28.02, p = 0.000); NEWQOL-6D: (F(2,1496) 
= 32.50, p = 0.000)), with a small to moderate effect size. For self-reported health the differences are 
significant (EQ-5D-3L: (F(2,1557) = 333.03, p = 0.000); NEWQOL-6D: (F(2,1505) = 212.72, p = 0.000)) with 
a moderate to large effect size.  A large effect size is seen for both measures between groups defined 
by impact of attack score (EQ-5D-3L: (F(1,808) = 127.33, p = 0.000); NEWQOL-6D: (F(1,793) = 174.07, p 
= 0.000)), and HADS-A  (EQ-5D-3L: (F(1,1526) = 418.51, p = 0.000); NEWQOL-6D: (F(1,1483) = 670.57, p 
= 0.000) and HADS-D (EQ-5D-3L (F(1,1538) = 625.82, p = 0.000); NEWQOL-6D (F(1,1493) = 792.24, p = 
0.000) cut off scores.  A moderate to large effect size for remission status was observed for both EQ-
5D-3L and NEWQOL-6D. 
 
Responsiveness  
EQ-5D-3L has a large ceiling effect at each time point, with between 31.6% UHSRUWLQJWKHµEHVW¶KHDOWK
state (11111) at baseline.  This may limit the ability of the descriptive system to measure increases in 
health, and is a common finding with EQ-5D-3L (Brazier et al., 2004). NEWQOL-6D does not have 
floor or ceiling effects.  Table 5 reports the responsiveness of EQ-5D-3L and NEWQOL-6D.  
NEWQOL-6D has larger a SRM than EQ-5D-3L for those who report remission in number of seizures 
and also improved health over the last year, with utility values improving . EQ-5D-3L is slightly more 
responsive in those that reported worsening health, although the SRMs are very similar.  Overall the 
SRMs are generally in the low to moderate range overall, with the largest SRMs reported between 
baseline and year one.  The frequency of respondents changing response category and overall utility 
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value varies for each of the preference based measure. NEWQOL-6D demonstrates a higher level of 
change than EQ-5D-3L between baseline and year 1 at the utility (85% vs. 62%) and response 
category level.  At the response level, the number of patients changing category ranges from 33% 
(stigma) to 60% (worry) change for NEWQOL-6D, and 12% (mobility) to 35% (anxiety/depression) for 
the EQ-5D-3L. 
 
Discussion 
There is some evidence from earlier research that EQ-5D-3L may not demonstrate a high level of 
validity for use in the measurement of HRQL in epilepsy [5-7].  We have carried out psychometric 
analysis to compare the recently developed epilepsy specific preference based measure NEWQOL-
6D and the EQ-5D-3L in a sample of patients with newly diagnosed focal epilepsy. This adds to the 
past work investigating the psychometric validity of the EQ-5D-3L, as well as establishing evidence 
about the validity of the NEWQOL-6D.   
 
The results suggest that there are similarities and differences between the measures, which impact 
on the psychometric characteristics, and are likely to affect subsequent cost effectiveness analyses. 
Firstly, the mean EQ-5D-3L scores are lower, and this is commonly found when comparing EQ-5D-3L 
to other generic and condition specific preference based measures due to comparative differences in 
the range of the utility scales and the concepts measured by the descriptive systems [21-22]. 
Secondly, in terms of convergence, the utility scales are moderately correlated, but there are low 
correlations between the descriptive systems.  This has been shown elsewhere [21-23] and suggests 
that these instruments are measuring some overlapping concepts, but there some important 
differences, and the utility scales, developed using the same method, are complementary.  
 
In terms of other differences between the descriptive systems, EQ-5D-3L has a large ceiling effect, a 
common finding [24] which suggests that EQ-5D-3L is not sensitive to small differences in health (i.e. 
the difference between none and some problems is too large to pick up small changes), but also 
cannot pick up improvements in health at follow up amongst those who report the best EQ-5D-3L 
health state at baseline.  NEWQOL-6D does not display a ceiling effect, and has a larger number of 
respondents changing the reported health state between time points, in part due to the number of 
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health states described (4096 vs. 243).  This may mean that NEWQOL-6D could be more sensitive in 
less severe epilepsy groups who are likely to be at the upper end of the utility scale.  It should be 
noted that the five level EQ-5D (EQ-5D-5L) [25] may help resolve the ceiling effect issue to some 
extent, and increases the number of health states to 3125.  EQ-5D-5L should now be considered for 
inclusion in trials where cost effectiveness analysis is required. EQ-5D-3L has a higher overall 
response rate, as it is administered as a five item questionnaire whereas NEWQOL-6D is derived 
from a much longer battery measure.  Furthermore, the EQ-5D-3L appeared before the instruments 
included in the NEWQOL battery [16] in the SANAD study questionnaire, and therefore the later 
measures may be affected by questionnaire fatigue.  However both have response rates over 90%. 
Finally, the recall period for EQ-5D relates WRµWRGD\¶, and this may limit its sensitivity in a chronic, 
episodic disease such as epilepsy.   
 
In terms of other psychometric indicators, the EQ-5D-3L and NEWQOL-6D perform similarly overall 
which suggests that both measures have validity for use in the economic evaluation of treatments for 
newly diagnosed focal epilepsy.  Both display generally good discriminant validity between clinical 
and general health severity groups, with the same category effect size.  Therefore both measures can 
be used with confidence to distinguish severity groups. Agreement between the measures is better at 
the less severe end of the utility scale, which is a common finding given differences in the range 
reported by the measures, with EQ-5D-3L having a larger range than most utility instruments [26]. 
The evidence for responsiveness is less clear.  There is an indication that NEWQOL-6D has slightly 
better responsiveness amongst those who report general health and seizure frequency improvement, 
but the measures are more similar when assessing those who report worsening health between time 
points.  Further research using clinical rather than self-reported indicators of change would be useful. 
 
The general determinants of HRQL in epilepsy, which is determined not just by efficacy but also by 
comorbidities, treatment safety and baseline severity of the condition [27] may provide context for 
some of the results reported.  For example, in terms of the descriptive system, both measures are 
highly sensitive to anxiety and depression which are well established epilepsy comorbidities that are 
related to HRQL regardless of seizure frequency [28].  However, anxiety and depression are not 
FRUUHODWHGHQWLUHO\ZLWKWUHDWPHQWHIILFDF\LQHSLOHSV\VRWKH\GRQ¶WHIIHFWmuch change in overall utility 
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in studies of antiepileptic treatment. It is therefore difficult to delineate the impact of HRQL in epilepsy 
on the sensitivity of and change in utility values measured (rather than at the dimension level) given 
the overall similar findings.  
 
The analysis reported here raises wider issues about the use and acceptability of generic and 
condition specific preference based measures.  For example, EQ-5D-3L allows for comparisons of 
utilities across health conditions which in some cases are limited by the psychometric validity of the 
instrument in that area.  By definition, condition specific measures do not allow for comparisons 
across health areas [29,30], but may provide a set of complementary utility values can be assessed 
alongside, for example, EQ-5D, to allow for more holistic measurement of the HRQL impacts of the 
condition. This might be particularly useful in settings where a particular measure is recommended, 
but evidence relating to that measure in certain health conditions is mixed (for example NICE 
recommending the EQ-5D in England) [12].  Furthermore, condition specific measures such as 
NEWQOL-6D may be limited in populations where there are comorbidities (as it is not designed to 
pick up changes in those). Further psychometric comparisons of generic and condition specific 
preference based measures across a range of health areas is warranted. 
 
The differences in the psychometric indicators may reflect in some ways into differences in cost 
effectiveness results, where the incremental cost-effectiveness ratio using NEWQOL-6D values may 
be different when compared with EQ-5D-3L.  Further work could investigate this issue in more detail 
across different trial datasets. 
 
There are limitations to this analysis.  Data were available from only one source (the SANAD trial that 
was also used to develop NEWQOL-6D) and replication of the results on a different sample with 
different external clinical indicators and types of epilepsy would be of interest. The time period studied 
in SANAD, where the measures were taken once a year over a two-year observation period is quite 
different to the typical RCT duration used for drug registration purposes.  We also did not have access 
to data about the type of seizure experienced by those included in SANAD, and this may have helped 
inform the utility values used. The baseline seizure frequency data is difficult to interpret, as a patient 
with 2 seizures in the 12 months prior to starting treatment may have had them in the space of a few 
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weeks before starting treatment, or over a longer period. The analysis could also not fully assess the 
responsiveness of the measures by varying levels of response to AED treatment as we could only 
define patients as seizure-free, or having one or more seizures.  Finally, using samples based on 
those fully completing each of the measures also excludes a number of respondents, and potentially 
those in poorer health who may have not managed to complete the long NEWQOL battery, but is a 
valid criterion given that we are trying to compare the performance of measures across matched 
samples. 
 
In conclusion, there is the indication that NEWQOL may better reflect differences across groups 
particularly at the least severe end but both measures perform at a similar level. .   Therefore there is 
some evidence that both the EQ-5D-3L and NEWQOL-6D have validity for providing utility values for 
use in the economic evaluation of interventions for newly diagnosed focal epilepsy, and subsequent 
decision making. Given the widespread use of EQ-5D-3L (and its use across conditions given its 
generic nature), and the subsequent development of the EQ-5D-5L which may increase 
responsiveness, both measures could be used alongside each other to provide complementary utility 
values from a generic and condition specific perspective, and more holistic measurement of HRQL in 
epilepsy. 
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Figure 1: Bland Altman plot at baseline of EQ-5D-3L and NEWQOL-6D 
 
Nb: The x axis is the mean utility score of the EQ-5D-3L and NEWQOL-6D, and the he y axis is the 
difference in utility score between the measures 
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Table 1: Background characteristics (baseline) 
 N (%) 
N              Baseline 1611 
Year 1 1288 
Year 2 1134 
Male 885 (55.2) 
Age  
Mean (SD) 39.7 (16.5) 
Range 16 ± 86  
In employment 1297 (78.8)  
Marital status  
Married/partner 885 (55.1) 
Single 548 (34.1) 
Divorced/separated 134 (8.3) 
Widowed 38 (2.4) 
EQ-5D-3L VAS   
Mean (SD) 68.14 (20.7) 
Range 5 ± 100  
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Table 2: Descriptive analysis of EQ-5D-3L and NEWQOL-6D utility scores 
 Baseline One year Two years 
EQ-5D-3L    
N fully completing (% completion) 1563 (98) 1244 (98) 1091 (98) 
Mean 0.735 (0.30) 0.769 (0.29) 0.789 (0.28) 
Median 0.848 0.848 0.848 
Range -0.38 to 1 -0.454 to 1 -0.239 to 1 
NEWQOL-6D         
N fully completing (% completion) 1508 (94) 1156 (90) 1023 (90) 
Mean 0.766 (0.13) 0.798 (0.13) 0.805 (0.13) 
Median 0.786 0.832 0.844 
Range 0.341 to 0.957 0.341 to 0.957 0.341 to 0.957 
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Table 3: EQ-5D-3L and NEWQOL-6D dimension level correlations (baseline) 
 EQ-5D-3L 
 Mobility Self-Care Usual activities Pain/discomfort Anxiety/depression 
NEWQOL-6D      
Worry 0.221 0.169 0.326 0.243 0.327 
Depression 0.235 0.217 0.355 0.303 0.633 
Memory 0.267 0.207 0.346 0.271 0.319 
Concentration 0.289 0.237 0.388 0.265 0.326 
Control 0.307 0.255 0.387 0.288 0.357 
Stigma 0.243 0.213 0.305 0.230 0.261 
 
 
 
  
 21 
 
Table 4: Known group validity of EQ-5D-3L and NEWQOL-6D utilities 
 EQ-5D-3L NEWQOL-6D 
 N Mean (SD) ES Sig N Mean (SD) ES Sig 
No of seizures last year (BL)    0.000    0.000 
1-3 474 0.811 (0.26)   468 0.802 (0.11)   
4-9 447 0.737 (0.29) 0.28  432 0.765 (0.12) 0.34  
10+ 625 0.676 (0.33) 0.21  599 0.738 (0.14) 0.23  
Self reported health         
Very good/excellent 545 0.893 (0.18)  0.000 515 0.830 (0.10)  0.000 
Good 581 0.787 (0.22) 0.59  554 0.776 (0.11) 0.54  
Fair/poor 482 0.489 (0.35) 1.35  439 0.678 (0.13) 0.89  
Remission status (Y1)         
No remission (>1 attack) 742 0.701 (0.32)  0.000 695 0.762 (0.13)  0.000 
Remission (0 attacks) 495 0.876 (0.20) 0.88  456 0.855 (0.10) 0.93  
Remission status (Y2)         
No remission (>1 attack) 513 0.700 (0.31)  0.000 479 0.756 (0.14)  0.000 
Remission (0 attacks) 573 0.869 (0.22) 0.77  540 0.849 (0.09) 1.03  
HADS-A cut off         
No case 743 0.880 (0.19)  0.000 718 0.840 (0.08)  0.000 
Possible case 785 0.599 (0.32) 1.48  767 0.696 (0.13) 1.80  
HADS-D cut off         
No case 1036 0.848 (0.20)  0.000 999 0.820 (0.09)  0.000 
Possible case 504 0.501 (0.34) 1.02  496 0.657 (0.13) 1.81  
ES: Effect size 
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Table 5: Responsiveness of EQ-5D-3L and NEWQOL-6D 
 T0-T1 T1-T2 
 Mean 
Utility 
Change 
SRM Mean 
Utility 
Change 
SRM 
EQ-5D-3L      
Overall 0.025 0.10 0.005 0.03 
Self-report health change anchor     
Improved 0.076 0.38 0.051 0.30 
Same 0.019 0.09 0.002 0.01 
Declined -0.092 0.29 0.084 0.35 
Seizure frequency     
Remission 0.045 0.23 0.031 0.18 
NEWQOL-6D      
Overall 0.027 0.27 -0.002 0.02 
Self-report health change anchor     
Improve 0.056 0.52 0.022 0.24 
Same 0.018 0.20 -0.008 0.11 
Decline -0.022 0.19 -0.036 0.31 
Seizure frequency     
Remission 0.047 0.53 0.019 0.23 
SRM = standardised response mean 
 
 
 
